Symbiotec Pharmalabs shares surge 19% to a new post-listing high after 10-year deal with European protein innovator

Symbiotech Pharmalabs' managing director Anil Satwani said this fermentation-driven protein marks a major milestone in creating the clean, nutritious alternatives that consumers increasingly seek. He said Symbiotec is well-positioned to serve the alternative protein, human nutrition and industrial bioporducts sectors.